{"DataElement":{"publicId":"3535444","version":"2","preferredName":"Patient Cisplatin Resistance Sensitivity Status","preferredDefinition":"Term to describe the determination of platinum-based treatment resistant/sensitivity status based on time interval from initial treatment to progressive disease.","longName":"PLAT_RES_SEN_STAT","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3535437","version":"1","preferredName":"Patient Cisplatin Resistance Sensitivity Status","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04)_A Resistance Process consists of activities of biologic molecules or complexes involved in processes that maintain immunity to, or counteract, defeat, or withstand the effects of, an antagonistic agent._Sensitivity; the ability to respond to physical stimuli or to register small physical amounts or differences._A condition or state at a particular time.","longName":"2233604v1.0:3535435v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3535435","version":"1","preferredName":"Cisplatin Resistance Process Sensitivity Status","preferredDefinition":"An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04):A Resistance Process consists of activities of biologic molecules or complexes involved in processes that maintain immunity to, or counteract, defeat, or withstand the effects of, an antagonistic agent.:Sensitivity; the ability to respond to physical stimuli or to register small physical amounts or differences.:A condition or state at a particular time.","longName":"C376:C41546:C25201:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Resistance Process","conceptCode":"C41546","definition":"A Resistance Process consists of activities of biologic molecules or complexes involved in processes that maintain immunity to, or counteract, defeat, or withstand the effects of, an antagonistic agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Sensitivity","conceptCode":"C25201","definition":"The ability to respond to physical stimuli or to register small physical amounts or differences.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5BAF2FD-9BBB-EE03-E040-BB89AD43185C","latestVersionIndicator":"Yes","beginDate":"2012-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-26","modifiedBy":"ONEDATA","dateModified":"2012-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5BAF2FD-9BCC-EE03-E040-BB89AD43185C","latestVersionIndicator":"Yes","beginDate":"2012-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3535439","version":"2","preferredName":"Cisplatin Resistance Process Sensitivity Status","preferredDefinition":"An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04)_A Resistance Process consists of activities of biologic molecules or complexes involved in processes that maintain immunity to, or counteract, defeat, or withstand the effects of, an antagonistic agent._A measure of the minimum change in an input signal that an instrument can detect._A condition or state at a particular time.","longName":"CISPL_RES_SEN_STAT","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"40","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Platinum resistant","valueDescription":"Cisplatin Resistance Process","ValueMeaning":{"publicId":"3535440","version":"1","preferredName":"Cisplatin Resistance Process","longName":"3535440","preferredDefinition":"An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04): A Resistance Process consists of activities of biologic molecules or complexes involved in processes that maintain immunity to, or counteract, defeat, or withstand the effects of, an antagonistic agent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Resistance Process","conceptCode":"C41546","definition":"A Resistance Process consists of activities of biologic molecules or complexes involved in processes that maintain immunity to, or counteract, defeat, or withstand the effects of, an antagonistic agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5BB542C-1A36-0AC1-E040-BB89AD433A0A","latestVersionIndicator":"Yes","beginDate":"2012-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C87DA437-52D0-9B2A-E040-BB89AD433062","beginDate":"2012-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-30","modifiedBy":"ONEDATA","dateModified":"2012-08-30","deletedIndicator":"No"},{"value":"No history of platinum based treatment","valueDescription":"No Cisplatin Personal Medical History","ValueMeaning":{"publicId":"3535443","version":"1","preferredName":"No Cisplatin Personal Medical History","longName":"3535443","preferredDefinition":"The non-affirmative response to a question.: An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04): an account of all medical events and problems a person has experienced.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Personal Medical History","conceptCode":"C18772","definition":"A record of a patient's background regarding health and the occurrence of disease events of the individual. In addition, personal medical history may be a variable in epidemiologic studies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5BB542C-1AAB-0AC1-E040-BB89AD433A0A","latestVersionIndicator":"Yes","beginDate":"2012-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C87DA437-52EE-9B2A-E040-BB89AD433062","beginDate":"2012-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-30","modifiedBy":"ONEDATA","dateModified":"2012-08-30","deletedIndicator":"No"},{"value":"Platinum sensitive","valueDescription":"Cisplatin Sensitivity","ValueMeaning":{"publicId":"3574970","version":"1","preferredName":"Cisplatin Sensitivity","longName":"3574970","preferredDefinition":"An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04): Sensitivity; the ability to respond to physical stimuli or to register small physical amounts or differences.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Sensitivity","conceptCode":"C25201","definition":"The ability to respond to physical stimuli or to register small physical amounts or differences.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C87DA437-5318-9B2A-E040-BB89AD433062","latestVersionIndicator":"Yes","beginDate":"2012-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C87DA437-5331-9B2A-E040-BB89AD433062","beginDate":"2012-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-30","modifiedBy":"ONEDATA","dateModified":"2012-08-30","deletedIndicator":"No"},{"value":"NA","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"3261243","version":"1","preferredName":"Not Applicable","longName":"3261243","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA2BBD66-6581-A6F2-E040-BB89AD4311D3","latestVersionIndicator":"Yes","beginDate":"2011-08-10","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-10","modifiedBy":"RAGUNATHANU","dateModified":"2024-02-05","changeDescription":"12/15/15 added N/A as alternate VM-tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"292A3840-5A09-8C83-E050-BB89AD433992","beginDate":"2016-01-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-01-12","modifiedBy":"ONEDATA","dateModified":"2016-01-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3535438","version":"1","preferredName":"Cisplatin Resistance Process Sensitivity Status","preferredDefinition":"An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04):A Resistance Process consists of activities of biologic molecules or complexes involved in processes that maintain immunity to, or counteract, defeat, or withstand the effects of, an antagonistic agent.:A measure of the minimum change in an input signal that an instrument can detect.:A condition or state at a particular time.","longName":"C376:C41546:C68816:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Resistance Process","conceptCode":"C41546","definition":"A Resistance Process consists of activities of biologic molecules or complexes involved in processes that maintain immunity to, or counteract, defeat, or withstand the effects of, an antagonistic agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Sensitivity","conceptCode":"C68816","definition":"A measure of the minimum change in an input signal that an instrument can detect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5BB542C-1A0F-0AC1-E040-BB89AD433A0A","latestVersionIndicator":"Yes","beginDate":"2012-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-26","modifiedBy":"ONEDATA","dateModified":"2012-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C87DA437-52BA-9B2A-E040-BB89AD433062","latestVersionIndicator":"Yes","beginDate":"2012-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-30","modifiedBy":"REEVESD","dateModified":"2016-01-12","changeDescription":"v2.0 replaces v1.0 with deletion of two permissible values","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2811715","version":"1","longName":"Duke University","context":"NCIP"},{"publicId":"2812724","version":"1","longName":"Duke U New CDEs","context":"NCIP"}]},{"publicId":"3886752","version":"1","longName":"For Review","context":"DCI","ClassificationSchemeItems":[{"publicId":"3891931","version":"1","longName":"For Review","context":"DCI"}]}],"AlternateNames":[{"name":"DCI","type":"USED_BY","context":"DCI"},{"name":"Theradex","type":"USED_BY","context":"Theradex"}],"ReferenceDocuments":[{"name":"Platinum based treatment resi","type":"Preferred Question Text","description":"Platinum based treatment resistant/sensitive status","url":null,"context":"NCIP"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Platinum status","url":null,"context":"Theradex"},{"name":"Alliance Text 1","type":"Alternate Question Text","description":"Platinum Sensitivity","url":null,"context":"Alliance"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C87DA437-533F-9B2A-E040-BB89AD433062","latestVersionIndicator":"Yes","beginDate":"2012-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-30","modifiedBy":"ZHWENDY","dateModified":"2023-09-01","changeDescription":"Curated to support Duke University clinical trial. v2.0 replaces v1.0 with a different set of permissible values","administrativeNotes":"9/1/2023: added AQT per cadsr0002804.wz","unresolvedIssues":null,"deletedIndicator":"No"}}